Actionnariat et activité des initiés pour ADC Therapeutics S.A. (ADCT): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $1.05 |
| Capitalisation | $134M |
| Bourse | NYSE |
| Pays | CH |
Transactions d'Initiés Récentes
| Date | Initié | Type | Actions | Valeur |
|---|---|---|---|---|
| 2026-06-30 | Zaki Mohamed | A-Award | 213,900 | |
| 2026-06-30 | GRAHAM PETER J | A-Award | 221,100 | |
| 2026-06-30 | Carmona Jose | A-Award | 203,700 | |
| 2026-06-30 | MALLIK AMEET | A-Award | 675,000 | |
| 2026-03-31 | Redmile Group, LLC | S-Sale | 196,229 | $736K |
| 2026-04-01 | Redmile Group, LLC | S-Sale | 169,265 | $643K |
| 2026-03-31 | Redmile Group, LLC | S-Sale | 188,407 | $707K |
| 2026-04-01 | Redmile Group, LLC | S-Sale | 162,517 | $617K |
| 2026-04-02 | Redmile Group, LLC | S-Sale | 2,634,506 | $8.6M |
| 2026-04-02 | Redmile Group, LLC | S-Sale | 2,529,491 | $8.3M |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $143.7M | $262.8M | $138.8M | $115.6M | $439.2M | $466.5M | $326.4M | $278.6M | $250.9M | $261.3M |
| Placements à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Créances | $5.9M | $1.9M | $372000 | $2.8M | $2.7M | $31.1M | $73.0M | $25.2M | $20.3M | $29.1M |
| Stocks | 0 | $293000 | $1.2M | 0 | 0 | $11.1M | $12.1M | $16.2M | $18.4M | $4.2M |
| Actifs Courants | $151.3M | $265.2M | $142.1M | $122.6M | $450.4M | $525.2M | $435.0M | $336.3M | $307.4M | $306.3M |
| Immobilisations Corporelles | $777000 | $1.1M | $1.5M | $6.3M | $4.8M | $11.2M | $10.3M | $16.1M | $13.4M | $1.3M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | $2.9M | $5.4M | $6.7M | $8.4M | $10.2M | $13.6M | $14.4M | 0 | 0 | 0 |
| Actifs Totaux | $155.1M | $271.9M | $150.6M | $137.7M | $513.7M | $618.0M | $490.9M | $354.8M | $322.0M | $323.1M |
| Dettes Fournisseurs | $2.1M | $7.6M | $6.8M | $3.3M | 0 | $12.1M | $12.4M | $15.6M | $18.0M | $9.2M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | $4.6M | $6.6M | $12.5M | 0 | 0 | $3.0M |
| Passifs Courants | $9.7M | $20.5M | $22.4M | $19.9M | $40.4M | $73.9M | $81.9M | $67.7M | $80.5M | $70.2M |
| Dette à Long Terme | 0 | 0 | 0 | 0 | $108.0M | $125.1M | $109.7M | $112.7M | $113.6M | $436.0M |
| Passifs Totaux | $14.2M | $22.8M | $24.3M | $26.5M | $178.2M | $451.9M | $411.4M | $503.0M | $524.6M | $509.0M |
| Réserves | -$119.1M | -$209.0M | -$332.1M | -$448.6M | -$694.9M | -$924.9M | -$1.10B | -$1.34B | -$1.49B | -$1.64B |
| Capitaux Propres | $140.9M | $249.2M | $126.2M | $111.2M | $335.5M | $166.1M | $79.5M | -$148.2M | -$202.6M | -$185.8M |
| Dette Totale | 0 | 0 | 0 | $5.0M | $115.1M | $139.7M | $129.8M | $124.4M | $123.0M | $439.0M |
| Dette Nette | -$143.7M | -$262.8M | -$138.8M | -$110.5M | -$324.1M | -$326.8M | -$196.6M | -$154.2M | -$127.9M | $177.7M |
| Fonds de Roulement | $141.6M | $244.6M | $119.7M | $102.7M | $410.0M | $451.2M | $353.0M | $268.6M | $226.9M | $236.2M |
Santé financière
| Dette / Capitaux propres | -1.83 |
| Ratio de liquidité | 3.03 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -6.54 |
Rentabilité
| Rentabilité des capitaux propres | 44.63% |
| Rentabilité du capital investi | -49.54% |
| Rentabilité des actifs | -34.69% |
| Marge brute | 88.75% |
| Marge opérationnelle | -125.83% |
| Marge nette | -123.03% |
Entreprises liées: ALMS · AUTL · BCYC · FDMT · LCTX · LXRX · NMRA
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de ADCT: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions